This is unpublished
back to the page outline
back to page outline

NASH - Nonalcoholic Steatohepatitis

Phase 3 treatment trials

NASH 747-304

Title: A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis
Condition & Intervention: Compensated Cirrhosis, NASH: Obeticholic Acid (oral)
PI: Bambha, Landis
Site: UWMC, HMC

NASH IDN-6556-17

Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects with Decompensated Non-Alcoholic Steatohepatitis (NASH) Cirrhosis
Condition & Intervention: Decompensated Cirrhosis: Emricasan (oral)
PI: Bambha, Landis
Site: UWMC, HMC

NASH 3152-301-002

Title: AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis
Condition & Intervention: NASH: Cenicriviroc (oral)
PI: Bambha, Landis
Site: UWMC, HMC

NASH GFT505-315-

Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Elafibranor in Patients with Nonalcoholic Steatohepatitis (NASH) and fibrosis 
Condition & Intervention: NASH with Fibrosis: Elafibranor (oral)
PI: Landis
Site: HMC

 Registry/observational Studies

NASH/NAFLD TARGET-NASH 

Title: A 5-year Longitudinal Observational Study of Patients with Nonalcoholic Fatty Liver Disease or Nonalcoholic Steatohepatitis
Condition & Intervention:
NASH/NAFLD - Patient Registry
PI: Landis
Site: HMC

NASH/NAFLD 16HEP01

Title: Procurement of Blood Samples from Subjects with Diagnosed Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) for Use in the Development of a Liver Fibrosis Test
Condition & Intervention: NASH - Fibrosis Stages (F0-F4)
PI: Landis
Site: HMC

 Phase 2 treatment trials

NASH EDP 305-101

Title: A Phase 2 Dose Ranging, Randomized, Double Blind, and Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis
Condition & Intervention:(NASH) NASH: EDP-305 (Oral)
PI: Landis
Site: HMC

Cirrhosis

Interventional Study

placeholder

The spotlight title goes here

The spotlight subtitle goes here.

 RED-C-3131

A Randomized, Double-blind Placebo-controlled, Multi-Center Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) Tablets for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C/3131) [Phase 3]

This research study aims to see if Rifaximin SSD-40IR (IND) given twice daily will help delay the first episode of overt hepatic encephalopathy (OHE) requiring hospitalization.

PI: Biggins

Site: UWMC

HCV - Hepatitis C Virus

Registry/observational Studies

HCV - TARGET

Title: Hepatitis C Therapeutic Registry and Research Network - A Longitudional, Observational Study
Condition & Intervention: HCV - patients being treated with treatments containing telaprvir or boceprevir
PI: Landis
Site: HMC

Open-label treatment studies

HCV Pro00069602

Title: A Multicenter, Open-label Study of Harvoni ® (Sofosbuvir Ledipasvir Fixed Dose Combination) in Subjects Infected With Chronic Hepatitis C and Advanced Heart Failure or Lung Disease
Condition and Intervention: Hep C, Heart Failure, Chronic Pulmonary Disease, Interstitial Lung Disease: Harvoni/Sofosbuvir/Ledipasvir
PI: Landis
Site: HMCThe spotlight subtitle goes here.

HCV B16-439

Title: A Phase 3b, Multi-Center, Randomized, Open-Label, Pragmatic Study of Glecaprevir/Pibrentasvir (G/P) +/- Ribavirin for GT1 Subjects With Chronic Hepatitis C Previously Treated With an NS5A Inhibitor + Sofosbuvir Therapy
Condition & Intervention: Hepatits C, HCV: Glacaprevir/Pibrentasvir 300mg, Ribavirin 200mg, Sofosbuvir 400mg (oral)
PI: Landis
Site: HMC

PBC - Primary Biliary Cholangitis

Registry/observational Studies

TARGET-PBC

Title: A 5-year Longitudinal Observational Study of Patients with Primary Biliary Cholangitis
Condition & Intervention: PBC - Patient Registry
PI: Landis
Site: HMC

Phase 2 treatment trials

PBC EDP 305-201

Title: A Phase 2 Dose Ranging, Randomized, Double Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Primary Biliary Cholangitis (PBC) With or Without an Inadequate Response to Ursodeoxy 
Condition & Intervention: PBC: EDP-305 (oral)
PI: Landis
Site: HMC

PSC - Primary Sclerosing Cholangitis

Phase 2 treatment trial

PSC EDP 305-201

Title: A Proof-of-Concept and Dose-Ranging Study Investigating the Efficacy and Safety of HTD1801 in Adult Subjects With Primary Sclerosing Cholangitis (PSC)
Condition & Intervention: PSC: HTD1801 (oral)
PI: Landis
Site: HMC

ALF - Acute Liver Failure

Observational study

A Mult-Center Group to Study Acute Liver Failure

Condition & Intervention: ALF/ALI
PI: Liou
Site: UWMC

HE - Hepatic Encephalopathy

Phase 2 treatment trial

OHE/HE RNHE2041

Title: A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) Tablets Plus Lactulose for the Treatment of Overt Hepatic Encephalopathy (OHE)
Condition & Intervention: OHE: Rifaximin and lactulose (oral)
PI: Biggins, Landis
Site: UWMC, HMC

HCC - Hepatocellular Carcinoma

Observational Study

TARGET-HCC

Title:  A 5-year Longitudinal Observational Study of the Natural History and Management of Patients With Hepatocellular Carcinoma (HCC)
Condition & Intervention:
Hepatocellular Cancer
PI: Landis
Site: HMC

Fatty Liver

Observational Study

DECT Liver Fat Quantification and Comparison with MR PDFF

This study aims to see if Dual-Energy CT (DECT), can accurately identify and quantify liver fat (hepatic steatosis). Our goal is to analyze image data acquired from routine DECT and determine the accuracy of liver fat quantification compared to the current clinical standard of MRI.

PI:Kolokythas/ Bambha

Site: UWMC

 

Additional topics

  • HBV - Hepatitis B Virus
  • HRS - Hepatorenal Syndrome
  • NAFLD - Nonalcoholic Fatty Liver Disease
  • AH - Alcoholic Hepatitis